Adaptimmune Therapeutics plc (MUN:473A)
0.0165
0.00 (0.00%)
At close: Apr 2, 2026
Adaptimmune Therapeutics Revenue
Adaptimmune Therapeutics had revenue of $13.68M USD in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.
Revenue (ttm)
$65.09M
Revenue Growth
-53.99%
P/S Ratio
0.08
Revenue / Employee
$128.63K
Employees
506
Market Cap
4.59M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 178.03M | 117.75M | 195.34% |
| Dec 31, 2023 | 60.28M | 33.13M | 122.05% |
| Dec 31, 2022 | 27.15M | 21.00M | 341.50% |
| Dec 31, 2021 | 6.15M | 2.19M | 55.36% |
| Dec 31, 2020 | 3.96M | 2.84M | 252.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest Aktiengesellschaft | 635.20M |
| 2invest AG | 28.07M |
| Darwin AG | 27.35M |
| Paion AG | 14.81M |
| co.don AG | 6.24M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| bioXXmed AG | 20.49K |